Remove Branding Remove Dermatology Remove FDA Approval
article thumbnail

SkinVive by Juvéderm: The New Dermal Filler Coming to the US

XTalks

Allergan Aesthetics, an AbbVie company renowned for its development of leading aesthetics brands and products, recently announced the US Food and Drug Administration (FDA) approved their ground-breaking hyaluronic acid product, SkinVive by Juvéderm, for achieving remarkable skin smoothness.

Filler 92
article thumbnail

Letybo Earns FDA Approval, Hugel Expands Its Global Aesthetic Market Leadership

XTalks

“We are thrilled with the FDA’s approval of Letybo. This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the US,” said James Hartman, president of Hugel America in the news release. “As

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. Food and Drug Administration (FDA) has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp. The FDA approval of Klisyri is a significant milestone for Athenex.

article thumbnail

Boehringer bags first approval for rare skin disease drug

pharmaphorum

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in the US. The flares can be serious enough to hospitalise patients with complications like heart failure, renal failure and sepsis.

Drugs 105
article thumbnail

Eflornithine (Iwilfin) Finally Gets Approval in a Cancer Indication with FDA Nod for High-Risk Neuroblastoma

XTalks

The US Food and Drug Administration (FDA) has approved Iwilfin (eflornithine) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have had at least a partial response to previous multiagent, multimodality therapy including anti-GD2 immunotherapy.

article thumbnail

Top 2020 Biopharma M&A Deals

The Pharma Data

The company has a number of branded products in this space, including Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. Soliris has been approved for paroxysmal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

And this year Eli Lilly stepped into the obesity drug market with its own GLP-1 weight loss drug Zepbound (tirzepatide), which the US Food and Drug Administration (FDA) approved in November of this year. report indicating that they accounted for half of the most viewed new brands. billion ad impressions.